• Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
This CME Activity has expired and is no longer available for credit.
Hepatitis C: Current Status and the Evolving Landscape

Hepatitis C: Current Status and the Evolving Landscape

Format

Webcast

Time to Complete

2 hours

Released

February 3, 2011

Expires

February 3, 2014

Maximum Credits

2.00 / CE for Pharmacists

Accredited Provider

This program is jointly sponsored by Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy, and Haymarket Medical Education.

If you have any questions relating to the accreditation of this activity, please contact vjclay@rci.rutgers.edu.

Mail:
Vickie Georgiana
Rutgers, The State University of New Jersey
Pharmacy Practice & Administration- Room 417E
160 Frelinghuysen Road,
Piscataway, NJ 08854

Program Description

This program enables pharmacists to stay current with the evolving landscape in the management of Hepatitis C. It includes a review of the disease, current treatment options, and agents in clinical development.

Originally provided live through Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, the goals in content development were for the participants to:

  • Understand the hepatitis C infection and disease progression
  • Recognize the unmet medical need for new treatment options for hepatitis C infection
  • Appreciate the relationship and influence of IL-28B on hepatitis C treatment
  • Summarize the current treatment options for hepatitis C
  • Understand the role of direct-acting antivirals in the future of hepatitis C treatment

Educational Objectives

After participating in this activity, pharmacists should be better able to:

Part 1: HCV: An Overview of Disease Progression and Factors Leading to New Treatment Options

  • Explain the etiology of hepatitis C infection and disease progression
  • Identify populations at risk of hepatitis C infection
  • State the challenges with current treatment options
  • Explain the rationale for new treatment options for hepatitis C infection

Part 2: Host Genetic Factors and Therapy Outcome: Focus on IL-28B
  • Define IL-28B
  • Discuss the relationship and influence of IL-28B on hepatitis C treatment
  • Identify patient populations in which IL-28B is relevant

Part 3: Current Status of Hepatitis C Treatment
  • Evaluate current treatments and treatment guidelines for hepatitis C
  • Discuss the rationale for current treatment guidelines
  • Identify issues and shortcomings of current treatments

Part 4: Evolving Landscape of Hepatitis C Treatment
  • Explain the role of direct-acting antivirals in the future of hepatitis C treatment
  • Identify issues with direct-acting antivirals
  • Describe the potential shift in standard of care towards triple combination therapy
  • Discuss the impact of interferon-free regimens

Disclosure of Conflicts of Interest

Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by Rutgers for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. Rutgers is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Bardia Akbari, PharmD
Global Head Partnering, Inflammation Head
Roche Rutgers Fellowship Program

Tierra Ryan, PharmD
Rutgers Pharmaceutical Industry Fellow

Anna Beryoskina, PharmD
Rutgers Pharmaceutical Industry Fellow

Dayton Yeun, PharmD
Rutgers Pharmaceutical Industry Fellow

Shevia Ghazanfari, PharmD
Rutgers Pharmaceutical Industry Fellow

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Bardia Akbari, PharmD
Tierra Ryan, PharmD
Anna Beryoskina, PharmD
Dayton Yeun, PharmD
Shevia Ghazanfari, PharmD

have nothing to disclose

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following Rutgers School of Pharmacy planner, Vickie Georgiana, Georgina Dall, and Jim Alexander, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Haymarket Medical Education planners and managers, hereby state the following financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months:

Lynne Callea, Director of CME & Custom Publishing, has nothing to disclose. Nick Zittell, Vice President, Editorial Director, is a Stockholder of Merck & Co and Johnson & Johnson. Jim Burke, RPh, Internet Manager, has nothing to disclose.

Credit

2.00

Type

CE for Pharmacists

Accreditation Statement

Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey designates this continuing education activity for 2.00 contact hour (2.00 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN) 0038-0000-10-017-L04-P

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy and Haymarket Medical Education, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better is required. This course is offered at $5.00 per credit to participants. (2.0 credits = $10.00 for this course). Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required